XOMA Royalty (XOMA) Other financing activities (2015 - 2024)
XOMA Royalty's (XOMA) quarterly Other financing activities came in at $79000.0 in Q3 2024, down 1.25% quarter-over-quarter from $80000.0 in Q2 2024.
XOMA Royalty (XOMA) Other financing activities (2015 - 2024) Analysis & Trends
XOMA Royalty has disclosed Other financing activities across 8 years of filings, most recently posting $79000.0 for Q3 2024.
- Other financing activities for Q3 2024 came in at $79000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $159000.0 (down 81.58% YoY), and the FY2024 annual result was $740000.0, down 82.6% from the prior year.
- Other financing activities came in at $79000.0 for Q3 2024 at XOMA Royalty, down from $80000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $3.0 million in Q2 2021 to a low of $20000.0 in Q3 2020.
- The 5-year median for Other financing activities is $123000.0 (2020), against an average of $482923.1.
- Peak annual rise in Other financing activities reached 2352.03% in 2021, while the deepest fall reached 92.01% in 2021.
- XOMA Royalty's Other financing activities stood at $1.7 million in 2020, then plunged by 92.01% to $137000.0 in 2021, then tumbled by 37.96% to $85000.0 in 2022, then jumped by 44.71% to $123000.0 in 2023, then sank by 35.77% to $79000.0 in 2024.
- The last three Other financing activities figures came in at $79000.0 (Q3 2024), $80000.0 (Q2 2024), and $581000.0 (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 79,000.00 |
| Sep 30, 2024 | 79,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 581,000.00 |
| Mar 31, 2024 | 581,000.00 |
| Mar 31, 2023 | 123,000.00 |
| Mar 31, 2023 | 123,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Mar 31, 2022 | 85,000.00 |
| Dec 31, 2021 | 137,000.00 |
| Dec 31, 2021 | 137,000.00 |
| Sep 30, 2021 | 142,000.00 |
| Sep 30, 2021 | 142,000.00 |
| Jun 30, 2021 | 3.02 Mn |
| Jun 30, 2021 | 3.02 Mn |
| Mar 31, 2021 | 90,000.00 |
| Mar 31, 2021 | 90,000.00 |
| Dec 31, 2020 | 1.71 Mn |
| Dec 31, 2020 | 1.71 Mn |